Över lag kom rapporten in enligt Analysguidens förväntningar.
Plejds nettoomsättning för det fjärde kvartalet 2023 uppgick till 161,9 MSEK, en ökning med 26,9 pro...
Higher sales and lower costs behind strong margin expansion We lift '24e EBIT by 12% on lower opex a...
Redeye returns with an update following Annexin’s Q4 report, and the company continued to present ad...
Q4 – allt under kontroll Ascelias rapport för det fjärde kvartalet innehöll inga överraskningar.
IRLAB has reported FY23 results and provided operational and regulatory updates, including an end-of...
Investors House reported Q4 revenues of EUR 1.8m, in line with our estimate.
Redeye anticipates that Physitrack’s Q4 2023 results will demonstrate robust cash generation, organi...
Order intake growth adds visibility Sports & outdoor demand should normalise during '24 '24e-'25e EB...
Northbaze Group AB has declared bankruptcy for its subsidiary, HAPJ AB, due to poor financial perfor...
Redeye states that Catella had a quarter with weaker-than-expected performance from Investment Manag...
Redeye comments on Freemelt’s agreement with WEAREAM, which marks an important step in the ongoing c...
Redeye reviews Alligator Bioscience’s fourth quarter and the rights issue announced on Thursday even...
Redeye updates on Better Collective following the announcement of preliminary results for 2023 which...
Redeye states that the report was below expectations.
Lower sales offset by margins as operational measures take effect EPS estimates largely intact due t...
Lower occupancy leads to negative est. revisions Acquisition potential remains, CEPS upside of ~20% ...
Q4 NOI margin on the softer side 80% floating debt drives estimate revisions 2024e P/CEPS of ~20.
Q4 hit by restructuring costs We lower estimates again Positive update on the cost savings for offic...
Organic earnings under pressure, but solid M&A '24e-'25e adj.
